Trellus Health PLC Result of AGM (6331D)

TIDMTRLS

RNS Number : 6331D

Trellus Health PLC

22 June 2023

Trellus Health plc

("Trellus Health" or the "Company")

Result of AGM

LONDON, U.K. AND NEW YORK, U.S. (22 June 2023). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The voting results of the AGM were as follows:

 
                   In Favour             Against       Withheld 
 Resolution     Votes         %       Votes      %      Votes 
             -----------  --------  --------  ------  --------- 
 1            43,559,167   100.00%      0      0.00%    1,171 
             -----------  --------  --------  ------  --------- 
 2            43,391,049   99.95%    21,961    0.05%   147,328 
             -----------  --------  --------  ------  --------- 
 3            43,401,966   99.97%    11,044    0.03%   147,328 
             -----------  --------  --------  ------  --------- 
 4            43,110,425   98.97%    448,742   1.03%    1,171 
             -----------  --------  --------  ------  --------- 
 5            43,108,985   98.97%    450,182   1.03%    1,171 
             -----------  --------  --------  ------  ---------

For further information please contact:

 
Trellus Health plc                                         https://trellushealth.com/ 
Dr. Marla Dubinsky, CEO and Co-Founder                                Via Walbrook PR 
Dr. Daniel Mahony, Chairman 
Steve Young, CFO 
 
Singer Capital Markets (Nominated                            Tel: +44 (0)20 7496 3000 
 Adviser and Broker) 
Aubrey Powell / Jen Boorer 
 
Walbrook PR                        Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com 
Paul McManus / Sam Allen /                    Mob: +44 (0)7980 541 893 / (0) 7748 651 
 Phillip Marriage                                               727 / (0)7867 984 082

About Trellus Health plc ( www.trellushealth.com )

Trellus Health (LSE: TRLS) is the first resilience based digital health company focused on the intersection of chronic illness and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden, building self-management skills and promoting positive health behaviours that improves outcomes and enables thriving in the face of a chronic condition. Through its TrellusElevate(TM) connected health platform and companion App, the company addresses both physical and behavioural health together, in context, to improve outcomes and reduce healthcare costs across the healthcare ecosystem.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both with over 50 years of combined clinical and research experience in IBD, IBS and psychogastroenterology, respectively.

The Company was initially focused on inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

The TrellusElevate(TM) platform is the Company's proprietary connected health platform that incorporates the GRITT(TM) methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes(1) .

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

(1) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258 )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUUOUROVUNUAR

(END) Dow Jones Newswires

June 22, 2023 08:37 ET (12:37 GMT)

Trellus Health (LSE:TRLS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024